ARTICLE | Clinical News
Atacand candesartan cilexetil: Began Phase III study
November 6, 2000 8:00 AM UTC
AstraZeneca plc (AZN), London, U.K. Product: Atacand candesartan cilexetil Business: Ophthalmic Therapeutic category: Receptor antagonist Target: Angiotensin II receptor Description: Small molecule a...